Halaven (Eribulin, E7389)


The name of this drug was mentioned yesterday at the SFA Educational Conference because large trials (likely phase III) are scheduled to start sometimes soon. I had never heard of this name so I did my little search and found the results from the European phase II study :


The response rate for synovial sarcoma is not very impressive unfortunately...


Phase III trial of eribulin in soft tissue sarcoma shows overall survival benefit in primary endpoint:


It's not clear whether there was any patient with synovial sarcoma in this study. We'll have to wait for the data.

Results of the phase 2 trial are here: